"As Gwyneth Paltrow Said": Astronomer CEO On Moving On From Kiss Cam Scandal
Now, Pete DeJoy, the new interim CEO, has said that the Astronomer crew proved last week, in full colour, that "character shines brightest in tough moments".
"They supported our customers, each other, and our mission without missing a beat. I'm deeply grateful to work alongside such thoughtful, driven people," he wrote in a LinkedIn post.
Apart from thanking the employees at Astronomer, Mr DeJoy also spoke about their "Maximum Effort for their remarkable work" with Academy Award-winning actor Gwyneth Paltrow, whom the company hired as a "temporary spokesperson".
"As Gwyneth Paltrow said, now it's time for us to return to what we do best: delivering game-changing results for our customers. We look forward to what this next chapter holds for Astronomer," he concluded.
Mr Dejoy's post came two days after the tech firm released a tongue-in-cheek ad featuring Gwyneth Paltrow to manage the fallout.
Ms Paltrow, the former wife of Coldplay lead singer Chris Martin, introduced herself as Astronomer's "very temporary spokesperson." Instead of addressing the scandal, she completely ignores the gossip and talks about what the company actually does.
She said, "I'm hired to speak on behalf of the 300-plus employees at Astronomer. Astronomer has gotten a lot of questions over the last few days and they wanted me to answer the most common ones."
The first question: "OMG! What the actual f***," a clear reference to the viral scandal. She ignored the question and answered it as "Astronomer is the best place to run Apache Airflow. Unifying the experience of running data, ML and AI pipelines at scale. We've been thrilled so many people have found a new interest in data workflow automation."
The next question: "How is your social media team holding up?" She again ignored and said, "There's still room available at our Beyond Analytics event in September. We will now be returning to what we do best: delivering game-changing results for our customers."
The ad was created in collaboration with Ryan Reynolds' creative agency, Maximum Effort.
Thank you for your interest in Maximum Effort, @astronomerio! We'll now get back to what we do best: motion pictures with Hugh Jackman, Fastvertising and Wrexham football. We'll leave data workflow automation to ̶G̶w̶y̶n̶e̶t̶h̶ ̶P̶a̶ Astronomer. pic.twitter.com/ayeo65Y0KC
— Maximum Effort (@MaximumEffort) July 27, 2025
Mr Byron and Ms Cabot were caught on camera during the British Band's famous 'Jumbotron segment' sharing an intimate moment in Boston last week. The duo was first put on leave. Mr Byron was the first to resign; Ms Cabot followed soon after.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
41 minutes ago
- Business Standard
Pharma Inc gears up for Day 1 launch of obesity drug in March 2026
As the global demand for next-generation diabetes and weight-loss therapies surge, Indian pharmaceutical companies are stepping up preparations to roll out generic versions of semaglutide—a blockbuster GLP-1 receptor agonist—once patent expires around March 2026. The generic launches will be significant, as the prices for the Indian consumer are expected to come down significantly from the current ₹17,000-26000 (monthly), thereby expanding the patient coverage. Dr. Reddy's Laboratories (DRL), Cipla, Sun Pharma, and Mankind Pharma, and others are ramping up peptide manufacturing, forming device partnerships, and aligning regulatory strategies to capture a share of the global GLP-1 market, estimated to cross $150 billion by decade's end. Hyderabad-based DRL is planning Day 1 launches in India and Brazil, part of a 2026 global rollout across 87 countries. 'The semaglutide launch is very important to us,' said CEO Erez Israeli. The company aims to price its product below Novo Nordisk's current ₹17,000 monthly offering. DRL is also working on 26 GLP-1 therapies, backed by a ₹2,700 crore FY26 capex plan to scale peptide and biosimilar production. Cipla is targeting first-wave launches through a mix of in-house and partner filings. 'We see GLP-1 as one of the biggest therapy opportunities in the last five years,' said Umang Vohra, MD and global CEO at the post earnings call. The company is building parts of its GLP-1 supply chain internally while leveraging partnerships to ensure scalability. Cipla is also crafting an affordable strategy for India's price-sensitive market, betting that post-patent price erosion will be offset by volume growth. Mankind Pharma aims to launch both oral and injectable semaglutide generics and is advancing MKP10241, a novel oral obesity drug in Phase 2 trials in Australia. Sun Pharma, meanwhile, is progressing its investigational GLP-1 molecule Utreglutide, targeted for launch in four to five years. It has secured Phase III approval for semaglutide trials in India, even as it reports negligible impact of GLP-1 drugs on its existing diabetes portfolio. The race for a piece of India's ₹628 crore anti-obesity market, however, comes at a time when the Indian courts and drug regulator body are looking to monitor the unregulated use of weight loss drugs. According to sources, the Central Drug Standards Control Organisation (CDSCO) has initiated work to form a panel after the Delhi High Court in July 2025 asked it to consult experts and relevant stakeholders to look into concerns arising out of approval for drug combinations being sold in the market for weight loss. The directive came in response to a public interest litigation filed by fitness entrepreneur Jitendra Chouksey, who had raised concerns about the marketing approval of drugs such as semaglutide, tirzepatide and liraglutide for weight management, despite limited safety data and the absence of India-specific clinical trials. While disposing of the petition, the court asked the drug regulator to respond to the petitioner within three months. At present, India has two officially available semaglutide brands: Rybelsus (oral) and Wegovy (injectable), both from Danish major Novo Nordisk. Rybelsus is approved for treating Type 2 diabetes, while Wegovy was launched in June 2025 for weight management. US-based Eli Lilly's tirzepatide drug, Mounjaro, is also available in India for obesity management. Analysts say the semaglutide opportunity is also fuelling India's peptide manufacturing ecosystem. 'Formulation is no longer enough—companies need full-stack execution,' said Nirali Shah, Pharma Analyst at Ashika Group, pointing to DRL, Cipla, and Sun Pharma's early moves to secure pen delivery partnerships. Contract development and manufacturing organisations (CDMOs) like Anthem Biosciences and Syngene are positioning themselves to capture a larger share of the growing peptide segment. Device manufacturers, too, are scaling up to meet rising demand for injection pens. India's peptide CDMO market, currently valued at $80 million, is growing at a CAGR of 14 per cent and could become a global supplier base for GLP-1 drugs, said Nilaya Varma, CEO of Primus Partners.
&w=3840&q=100)
Business Standard
41 minutes ago
- Business Standard
JAL insolvency: Jaiprakash Infratech to challenge bid rejection in court
Jaiprakash Infratech Ltd, the New Delhi-based real estate firm, is preparing to challenge in court the rejection of its bid to acquire Jaiprakash Associates Ltd (JAL), potentially dragging the bankrupt cement and infrastructure major's resolution into further delay. Lenders of JAL had turned down Jaiprakash Infratech's offer, citing an insufficient earnest money deposit (EMD), according to people familiar with the matter. The company had proposed a lien over fixed deposits in lieu of the ₹100 crore deposit, but the bid was rejected for not submitting the amount in the prescribed format and for delays in filing the offer. 'The lien over the fixed deposits was legally valid and submitted on time,' said a person close to the company, who asked not to be named as the discussions were private. 'We have no option but to move the court and remain in the race.' Jaiprakash Infratech, which was taken over by Mumbai-based Suraksha Group in June 2024, is currently focused on completing long-pending housing projects for customers who have waited over a decade. JAL, on the other hand, was sent for debt resolution after the company defaulted on loans worth ₹57,000 crore to Indian lenders. In March this year, the lenders transferred their outstanding dues to National Asset Reconstruction Company. The fresh legal dispute threatens to complicate the resolution process, with Gautam Adani's group emerging as the frontrunner to acquire the company after submitting an unconditional bid. Other suitors, including Dalmia Bharat, Vedanta Group, Jindal Power and PNC Infratech, have submitted offers with conditions attached. Lenders have now asked all bidders to submit revised proposals without conditions. Several of the conditional offers hinge on the fate of JAL's 1,000-hectare Sports City project in Greater Noida. In March, the Allahabad High Court upheld the cancellation of land allotment for the project by the Yamuna Expressway Industrial Development Authority. That decision is currently under appeal in the Supreme Court.
Time of India
an hour ago
- Time of India
IIM graduate asked, 'How many kids do you have?' She vents, 'No one wanted to know my experience and achievements'
A seasoned marketing professional was forced to swallow a bitter pill when she was rejected for the position of CMO by a consumer brand, not for bombing the interview or for having unsatisfactory credentials, but for being a mom with growing kids. Taking to LinkedIn, the IIM alumna shared her ordeal and revealed that during the interview, the hiring manager asked borderline invasive questions about her family, and no queries were made about her leadership experience and domain knowledge. Along with the post, she also shared a screenshot of a WhatsApp chat between her and the hiring manager in which they confirmed her worst fears: she wasn't considered for being a mother. A Brief Interview Overshadowed by Personal Questions The interview, which lasted just 14 minutes, was conducted over the phone by the company's promoter. For the first 11 minutes, the candidate outlined her professional journey, summarizing her 11 years of marketing experience as requested. However, what followed was both unexpected and disappointing. In the remaining three minutes of the conversation, she was asked a string of personal questions, all related to her family rather than her work achievements. Explore courses from Top Institutes in Please select course: Select a Course Category Artificial Intelligence PGDM Public Policy Finance Operations Management Leadership Digital Marketing Data Analytics CXO healthcare Cybersecurity MCA Management Others Design Thinking Project Management Degree Data Science MBA others Technology Healthcare Product Management Data Science Skills you'll gain: Duration: 7 Months S P Jain Institute of Management and Research CERT-SPJIMR Exec Cert Prog in AI for Biz India Starts on undefined Get Details She was queried about the size of her family, the number of children she had, their ages, where her older child studied, and who took care of them in her absence. Even her mode of daily commute and her husband's career and the performance of his startup were questioned. The only vaguely professional query was about why she had exited her previous job. Throughout the interaction, there was no mention of her leadership qualities, her record of increasing revenues, her contribution to business growth, her accomplishments in challenging roles, or even her areas of improvement. "No further questions on my experience, revenue I handled, businesses I grew, industries I worked in, my achievements, my failures, challenging projects I worked on, or amazing work that I have ever delivered. Not even my strengths and weaknesses!" she wrote. It became immediately clear to her that the outcome of the interview was already predetermined. She followed up with HR the following day, only to have her worst suspicions confirmed in a WhatsApp chat—she was not selected due to her identity as a mother. A Broader Problem: Maternity Bias and Professional Setbacks What makes this incident more troubling is that this isn't an isolated case. The woman emphasized that her post wasn't a complaint about missing out on a role—she didn't particularly need or want that job—but rather a spotlight on the pervasive problem of discrimination against working mothers . She explained how many of her highly qualified friends, some from elite institutes and top-tier professional backgrounds, have experienced similar treatment. In many cases, women with children are either overlooked for promotions, subjected to token salary increases, or placed in roles deemed "easier" due to their perceived family obligations. This unfair bias, often referred to as the "maternity penalty," is deeply entrenched in workplace culture. It sidelines capable women solely based on their reproductive choices, denying them fair opportunities to grow in their careers. Gender Disparity at the Top Over the past few months, the candidate noted a disturbing pattern while applying for senior-level roles. Most leadership positions in both emerging start-ups and well-established corporations are overwhelmingly occupied by men. Although she holds no prejudice against male leaders, her observation makes it evident that gender disparity in leadership is far from being addressed. In fact, she predicted that the company she interviewed with would likely appoint a man for the CMO role. Redditors React The WhatsApp screenshot shared by the IIM graduate quickly gained traction, spreading across LinkedIn and the subreddit Indian Workplace. Users on Reddit were quick to confirm that such discriminatory practices during interviews are, unfortunately, all too common in many Indian workplaces . Several contributors to the discussion shared similar experiences, stating that some employers explicitly prefer hiring young, unmarried individuals under the assumption that they will be more committed to work and free from familial responsibilities. Others mentioned that even single women often face intrusive questions about their personal lives, including whether they plan to get married soon. Married women, especially those without children, are frequently asked about their husbands' professions, potential plans to relocate, and intentions around starting a family. Many described how interviewers in corporate India frequently behave more like overly inquisitive neighborhood elders than professional recruiters. The woman at the center of this viral post has been identified as Pragya, a graduate of IIM Kozhikode.
